EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische StudieÄquivalenzstudieOpen Access · CC BY-NC 4.0

HIgh Power short duration radiofrequency ablation or cryoballoon ablation for paroxysmal Atrial Fibrillation (HIPAF trial)

Arian Sultan iD, Sven Kreutzer iD, Jonas Wörmann iD, Jakob Lüker iD, Jana Ackmann iD, Jan-Hendrik Schipper iD, Jan van den Bruck iD, Karlo Filipovic iD, Cornelia Scheurlen iD, Kerstin Rosenberger iD, Daniel Steven iD

Europace · 2025

DOI: 10.1093/europace/euaf066 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2025. Verfasst von Arian Sultan und 10 weiteren Autor:innen. Beteiligte Einrichtung: St. Georg Heart Centre Hamburg, Asklepios Clinic Hamburg, Lohmühlenstrasse 5, 20099 Hamburg, Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cryosurgery, Pulmonary Veins, Catheter Ablation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Pulmonary vein isolation (PVI) is a first-line treatment option for paroxysmal atrial fibrillation (PAF). Radiofrequency ablation (RFA) or cryoballoon ablation (CBA) are commonly used modalities. Recent studies demonstrated the superiority and potential benefits of very high-power short-duration (vHPSD) RFA using 70 W compared to conventional RFA (<50 W). Prospective randomized data comparing vHPSD RFA with 70 W with the frequently used CBA in the setting of PAF are lacking. Methods and results We conducted a randomized non-inferiority trial involving 170 patients undergoing de novo PVI for PAF. Patients were randomly assigned in a 1:1 ratio to undergo vHPSD RFA or to receive CBA. The composite primary endpoint consisted of (i) any atrial arrhythmia, (ii) new antiarrhythmic drug (AAD) onset, and (iii) re-ablation during 1 year after index procedure. The non-inferiority margin was predefined as a 10% lower 1-year event-free survival rate in vHPSD compared to CBA (delta = −0.1). A total of 170 patients with symptomatic PAF were enrolled and assigned to undergo de novo PVI, with 84 receiving vHPSD and 86 undergoing CBA. The overall study population had a mean age of 65 ± 11 years and included 50.6% women. For vHPSD PVI a 70 W/7 s anterior and 70 W/5 s posterior protocol including 3D mapping was used. Cryoballoon ablation was performed as usual. Successful PVI was achieved in all patients. Overall procedure time for vHPSD was significantly longer (81.1 ± 20.0 vs. 67.7 ± 17.2 min; P < 0.001). However, the mere ablation time was comparable (39.3 ± 15.5 vs. 36.7 ± 14.5 min; P = 0.285). Fluoroscopy time and amount of contrast medium were significantly lower for vHPSD PVI (9.2 ± 3.6 vs. 10.5 ± 4.3 min; P = 0.031; 15.5 ± 5.8 vs. 43.1 ± 30.0 mL; P < 0.001). Complication rates were comparable between groups. One pulmonary vein stenosis occurred after vHPSD. Three pericardial effusions and two transient ischaemic attack were reported after CBA. After a median follow-up of 367 days, 73.8% [n = 62, 95% confidence interval (CI): 63.1–82.8%] of patients in the vHPSD PVI group and 81.4% (n = 70, 95% CI: 71.6–89.0%) in the CBA group remained free of any event. Non-inferiority of vHPSD PVI compared to CBA PVI could not be demonstrated, with a difference of −0.076 [95% CI: (−0.201 to 0.049)] in event-free survival rates off AADs, as the 95% CI includes the delta of −0.1.

Conclusion

In this randomized non-inferiority trial comparing vHPSD RFA to CBA for PVI in patients with PAF, non-inferiority of vHPSD RFA could not be shown. Both methods showed comparable safety outcome with a shorter procedure time for CBA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCryosurgeryPulmonary VeinsCatheter AblationHumansFemaleMaleMiddle AgedAgedTime FactorsProspective StudiesTreatment OutcomeAnti-Arrhythmia AgentsRecurrenceProgression-Free Survival

Stichwörter der Autor:innen

Trial testing non-inferiority of vHPSD vs Cryo in PAF patients

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • St. Georg Heart Centre Hamburg, Asklepios Clinic Hamburg, Lohmühlenstrasse 5, 20099 Hamburg, Germany.
  • Department of Electrophysiology, Heart Centre University Hospital Cologne, Kerpener Strasse 62, Cologne 50937, Germany.
  • Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

ORCID-Profile: Arian Sultan, Sven Kreutzer, Jonas Wörmann, Jakob Lüker, Jana Ackmann, Jan-Hendrik Schipper, Jan van den Bruck, Karlo Filipovic, Cornelia Scheurlen, Kerstin Rosenberger, Daniel Steven

Förderung

  • German Heart Foundation

Zitieren

APA

Sultan, A., Kreutzer, S., Wörmann, J., Lüker, J., Ackmann, J., Schipper, J. H., van den Bruck, J., Filipovic, K., Scheurlen, C., Rosenberger, K., & Steven, D. (2025). HIgh Power short duration radiofrequency ablation or cryoballoon ablation for paroxysmal Atrial Fibrillation (HIPAF trial). Europace. https://doi.org/10.1093/europace/euaf066

Vancouver

Sultan A, Kreutzer S, Wörmann J, Lüker J, Ackmann J, Schipper JH, et al. HIgh Power short duration radiofrequency ablation or cryoballoon ablation for paroxysmal Atrial Fibrillation (HIPAF trial). Europace. 2025. doi:10.1093/europace/euaf066

BibTeX
@article{Sultan2025,
  author = {Sultan, Arian and Kreutzer, Sven and Wörmann, Jonas and Lüker, Jakob and Ackmann, Jana and Schipper, Jan-Hendrik and van den Bruck, Jan and Filipovic, Karlo and Scheurlen, Cornelia and Rosenberger, Kerstin and Steven, Daniel},
  title = {HIgh Power short duration radiofrequency ablation or cryoballoon ablation for paroxysmal Atrial Fibrillation (HIPAF trial)},
  journal = {Europace},
  year = {2025},
  doi = {10.1093/europace/euaf066}
}
Kostenlos starten →